BPS Bioscience Inc.
中级会员 | 第3年

当前位置:BPS Bioscience Inc.>>细胞库 / 细胞培养>> CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line

CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line

参  考  价面议
具体成交价以合同协议为准

产品型号

品       牌BPS Bioscience

厂商性质生产商

所  在  地

更新时间:2023-10-12 09:14:47浏览次数:216次

联系我时,请告知来自 化工仪器网
数量:1供应商:BPSBioscience细胞类型:稳转细胞系品系:Jurkat(cloneE6-1)
  • 数量:

    1

  • 供应商:

    BPS Bioscience

  • 细胞类型:

    稳转细胞系

  • 品系:

    Jurkat (clone E6-1), human T lymphoblast, suspension

  • 组织来源:

    /

  • 相关疾病:

    多种

  • 免疫类型:

    多种

  • 器官来源:

  • 运输方式:

    干冰

  • 年限:

    10

  • 生长状态:

    良好

  • CAS号:

  • 英文名:

    CD8+ TCR Knockout NFAT-Luciferase Reporter Jurkat Cell Line

  • 注册证号:

    /

  • 规格:

    2管

This cell line was generated from TCR Knockout NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #78556) by exogeneous overexpression of human CD8 (NM_001768.6) using lentiviral transduction (CD8a Lentivirus, BPS Bioscience #78648). To achieve knockout of TCR (T Cell Receptor), the TRAC (T-Cell Receptor Alpha Constant) and TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from recombinant Jurkat cells stably expressing the firefly luciferase gene under the control of NFAT response elements.TCRα/β knockout in the TCR Knockout NFAT-Luciferase Reporter Jurkat cells was confirmed by genomic sequencing and by flow cytometry and expression of CD8 was confirmed by flow cytometry. The cell line has been functionally validated and does not respond to anti-CD3 agonist antibodies, as opposed to parental NFAT-Luciferase Reporter Jurkat cells (BPS Bioscience #60621).

会员登录

×

请输入账号

请输入密码

=

请输验证码

收藏该商铺

X
该信息已收藏!
标签:
保存成功

(空格分隔,最多3个,单个标签最多10个字符)

常用:

提示

X
您的留言已提交成功!我们将在第一时间回复您~
拨打电话
在线留言